Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB27 vs Keytruda in resected stage II-IIIA NSCLC
NCT06268613Phase 1Active, not recruiting
- Sponsor
- Samsung Bioepis
- Start
- Jan 2024
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Samsung Bioepis. Primary endpoint: Area Under the Concentration-time Curve over the Dosing Interval. Started Jan 2024; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06268613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268613.